These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 16595916

  • 1. Multiple regression analysis of pharmacogenetic variability of carvedilol disposition in 54 healthy Japanese volunteers.
    Honda M, Ogura Y, Toyoda W, Taguchi M, Nozawa T, Inoue H, Hashimoto Y.
    Biol Pharm Bull; 2006 Apr; 29(4):772-8. PubMed ID: 16595916
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. UGT2B7*3 did not affect the pharmacokinetics of R- and S-carvedilol in healthy Japanese.
    Honda M, Toyoda W, Shimizu T, Horiuchi I, Kayano Y, Taguchi M, Nozawa T, Inoue H, Hashimoto Y.
    Drug Metab Pharmacokinet; 2007 Oct; 22(5):382-6. PubMed ID: 17965522
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis.
    Takekuma Y, Takenaka T, Kiyokawa M, Yamazaki K, Okamoto H, Kitabatake A, Tsutsui H, Sugawara M.
    Biol Pharm Bull; 2007 Mar; 30(3):537-42. PubMed ID: 17329852
    [Abstract] [Full Text] [Related]

  • 5. Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure.
    Saito M, Kawana J, Ohno T, Hanada K, Kaneko M, Mihara K, Shiomi M, Nagayama M, Sumiyoshi T, Ogata H.
    Biol Pharm Bull; 2010 Mar; 33(8):1378-84. PubMed ID: 20686235
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of R- and S-carvedilol in routinely treated Japanese patients with heart failure.
    Horiuchi I, Nozawa T, Fujii N, Inoue H, Honda M, Shimizu T, Taguchi M, Hashimoto Y.
    Biol Pharm Bull; 2008 May; 31(5):976-80. PubMed ID: 18451529
    [Abstract] [Full Text] [Related]

  • 7. Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients.
    Nardotto GHB, Lanchote VL, Coelho EB, Della Pasqua O.
    Eur J Pharm Sci; 2017 Nov 15; 109S():S108-S115. PubMed ID: 28522373
    [Abstract] [Full Text] [Related]

  • 8. Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.
    Yoo HD, Cho HY, Lee YB.
    Br J Clin Pharmacol; 2010 Jan 15; 69(1):27-37. PubMed ID: 20078610
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
    Mouly SJ, Matheny C, Paine MF, Smith G, Lamba J, Lamba V, Pusek SN, Schuetz EG, Stewart PW, Watkins PB.
    Clin Pharmacol Ther; 2005 Dec 15; 78(6):605-18. PubMed ID: 16338276
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety.
    Xiang Q, Zhao X, Zhou Y, Duan JL, Cui YM.
    J Clin Pharmacol; 2010 Jun 15; 50(6):659-66. PubMed ID: 20332423
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.